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Objective: A prospective randomized multicenter study was per-
formed to assess whether the results of pylorus-preserving pancre-
aticoduodenectomy (PPPD) equal those of the standard Whipple
(SW) operation, especially with respect to duration of surgery, blood
loss, hospital stay, delayed gastric emptying (DGE), and survival.
Summary Background Data: PPPD has been associated with a
higher incidence of delayed gastric emptying, resulting in a pro-
longed period of postoperative nasogastric suctioning. Another crit-
icism of the pylorus-preserving pancreaticoduodenectomy for pa-
tients with a malignancy is the radicalness of the resection. On the
other hand, PPPD might be associated with a shorter operation time
and less blood loss.
Methods: A prospective randomized multicenter study was per-
formed in a nonselected series of 170 consecutive patients. All
patients with suspicion of pancreatic or periampullary tumor were
included and randomized for a SW or a PPPD resection. Data
concerning patients’ demographics, intraoperative and histologic
findings, as well as postoperative mortality, morbidity, and fol-
low-up up to 115 months after discharge, were analyzed.
Results: There were no significant differences noted in age, sex
distribution, tumor localization, and staging. There were no differ-
ences in median blood loss and duration of operation between the 2
techniques. DGE was observed equally in the 2 groups. There was
only a marginal difference in postoperative weight loss in favor of
the standard Whipple procedure. Overall operative mortality was
5.3%. Tumor positive resection margins were found for 12 patients
of the SW group and 19 patients of the PPPD group (P  0.23).
Long-term follow-up showed no significant statistical differences in
survival between the 2 groups (P  0.90).
Conclusions: The SW and PPPD operations were associated with
comparable operation time, blood loss, hospital stay, mortality,
morbidity, and incidence of DGE. The overall long-term and dis-
ease-free survival was comparable in both groups. Both surgical
procedures are equally effective for the treatment of pancreatic and
periampullary carcinoma.
(Ann Surg 2004;240: 738–745)
Pancreatic cancer is one of the most fatal malignant dis-eases today and ranks fifth in cancer mortality worldwide.
Survival after surgery is still disappointing, with 5-year
survival rates ranging from 10% to 29%.1–6
The introduction of partial pancreaticoduodenectomy is
credited to Godivilla, an Italian surgeon, and Kausch,7 a
German surgeon from Berlin. Later on, this technique was
refined by Whipple et al.8
Several modifications have been reported, including the
pylorus-preserving pancreaticoduodenectomy (PPPD) de-
scribed by Watson in 1944.9
This technique was reintroduced by Traverso and
Longmire10 in the late 1970s for chronic pancreatitis. Pres-
ervation of the pylorus in pancreaticoduodenectomy has been
shown in retrospective studies to lead to a long-term improve-
ment in gastrointestinal function, as indicated by more post-
operative weight gain, fewer peptic ulcers, and less dumping.
Furthermore, the pylorus preserving procedure simplifies the
operation, thus leading to shorter operations and less intra-
operative blood loss.11 Initial studies reported a high inci-
dence of complications, including delayed gastric emptying,
ulcerative lesions of the anastomosis,12,13 and concern about
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resection margins.5,14 Nevertheless, similar survival rates
have been described for both techniques.2,15–18
Only 2 relatively small studies have been performed to
study PPPD prospectively. In a prospective randomized study
of 31 patients by Lin and Lin,17 no differences in operation
time, blood loss, and blood transfusion were observed. De-
layed gastric emptying was observed more frequently after
PPPD than after the Whipple procedure, with marginal sta-
tistical significance (P  0.08). Seiler et al19 found shorter
operation time, less blood loss, and fewer blood transfusions
in the PPPD group of their series of 77 patients. No difference
in operative mortality was found, but the SW group exhibited
a higher morbidity rate.
In a large randomized trial in which the extended
retroperitoneal lymphadenectomy for periampullary adeno-
carcinoma was compared with a standard resection to pre-
serve the pylorus,20,21similar mortality and some increased
morbidity in the extended resection group were reported.
We conducted a prospective randomized multicenter
study to evaluate whether PPPD has an advantage over the
standard Whipple (SW) procedure.
METHODS
Study Design
The study protocol was approved by the ethics committee
of each center. Informed consent was obtained according to the
local rules prevailing at each participating institution.
The following hospitals in the Netherlands participated:
Erasmus Medical Center Rotterdam; University Hospital
Maastricht; Leiden University Medical Center; Ignatius Hos-
pital, Breda; Reinier de Graaf Gasthuis, Delft; De Weezen-
landen Hospital, Zwolle, and Medical Center Leeuwarden.
The design of this prospective multicenter trial con-
sisted of a pretreatment evaluation and a randomized treat-
ment with either a SW or a PPPD. The postoperative mor-
bidity and mortality data were evaluated every 3 months up to
115 months of follow-up.
Preoperative Evaluation
Preoperative workup was standardized in all centers. A
CT scan of the upper abdomen and a chest x-ray were
requested. In most cases, an ERCP also was performed.
Percutaneous transhepatic cholangiography, angiography,
CT-angiography and MRI were optional.
Inclusion Criteria
We included 170 consecutive patients between January
1992 and December 2000 with suspected pancreatic or peri-
ampullary cancer that was assumed to be resectable according
to preoperative diagnostic imaging (CT and/or MRI). Patients
with a previous gastric resection were excluded.
Exclusion Criteria
Patients with distant metastasis or local unresectable
tumors, as indicated by preoperative workup and intraopera-
tive findings, were excluded. Patients with direct invasion of
the pylorus or stomach, as well as patients with positive
peripyloric lymph nodes, were excluded; all of the remaining
patients were included in the analysis for efficacy. However,
for analysis of survival, patients with lesions other than
pancreatic or periampullary adenocarcinoma were excluded.
Blinding and Randomization
An equal number of blind envelopes with protocols for
the SW and the PPPD resection was prepared. The envelopes
were used sequentially as patients were enrolled in the study.
Therefore, there was strict randomization in both arms. Ran-
domization was carried out in the operation room: a sealed
envelope was opened only after it was ascertained that both
operation techniques were feasible in the patient concerned.
Eighty-seven patients were randomized for PPPD (50 male:
37 female) with a median age of 64 years. Eighty-three
patients were randomized for a Whipple resection (58 male:
25 female), with a median age of 62 years. Two patients in
the PPPD group were converted to the SW resection during
operation as the surgeon expected duodenal involvement;
these 2 patients remained for analysis in the PPPD group.
Surgery
All patients were placed on a regimen of prophylactic
antibiotics consisting of 2 g cefazolin (Cefacidal, Bristol-
Meyers Squibb, Woerden, Holland) and 500 mg metronidazol
(Flagyl, Aventis Pharma, Hoevelaken, Holland). In addition,
octreotide (Sandostatin, Novartis Pharma, Arnhem, Holland)
was administered to all patients preoperatively and continued
postoperatively for 7 days at a dosage of 100 g given
subcutaneously 3 times a day.22
Surgical Procedure
The standard, pylorus-preserving resection involved
division of the duodenum 2 cm distal to the pylorus with
resection of all of the duodenum distal to the transection site,
removal of the gallbladder and common bile duct (proximal
to the level of the cystic duct junction), resection of the head,
neck, and uncinate process of the pancreas (underneath the
superior mesenteric vein, lateral from the mesenteric-portal
vein axis, flush with the superior mesenteric artery) and
removal of the periampullary tumor. For the standard resec-
tion, a distal gastrectomy varying from 20% to 40% was
performed. Frozen section was performed routinely at the
transection site of the pancreatic remnant in all patients. In
case of macroscopically suspected other margins, a frozen
section of this margin was also performed. An end-to-side
invaginated pancreaticojejunostomy was performed. Further
downstream, an end-to-side hepaticojejunostomy and side-to-
Annals of Surgery • Volume 240, Number 5, November 2004 Pancreaticoduodenectomy Versus Standard Whipple Procedure
© 2004 Lippincott Williams & Wilkins 739
side gastroenterostomy or an end-to-side pylorus-jejunos-
tomy was made.
Postoperative Management
All patients were managed according to a standard
postoperative pathway. All patients received histamine H2-
receptor antagonists as prophylaxis against stress ulceration,
and octreotide treatment was continued for 7 days. At the end
of the operation, a drain was left in the area of the pancre-
aticojejunostomy and the hepaticojejunostomy. The drain
was removed if the amylase concentration was less than 300
U/L (less than twice the serum concentration) and production
was less than 50 mL per day or after postoperative day 10.
Pancreatic fistula was defined as drainage of more than 50 mL
amylase-rich fluid per day through the surgically placed
drains on or after postoperative day 10 or pancreatic anasto-
motic disruption demonstrated radiographically.
A biliary fistula was diagnosed if there was persistent
secretion of bilirubin-rich drainage fluid of more 50 mL per
day or after the 10th postoperative day.
Postoperative bleeding was defined as the need for
more than 2 units of red blood cells more than 24 hours after
surgery or relaparotomy for bleeding.
The nasogastric tube was removed when the production
has decreased to less than 200 mL per 24 hours.
Delayed gastric emptying was defined as gastric stasis
requiring nasogastric intubation for 10 days or more or the
inability to tolerate a regular diet on the14th postoperative
day.23
Nineteen (10 SW and 9 PPPD) patients received post-
operative chemoradiotherapy according to the EORTC study
in which the Erasmus Medical Center Rotterdam patici-
pated.24
Pathologic Review
All pathology specimens were reviewed to determine
the primary pathologic diagnosis and the extent of the dis-
ease. Tumor stage was determined according to the UICC
classification system and the TNM system.25 Resection mar-
gins of the specimen were stained and were considered
positive if the neoplasm was present at the pancreatic neck,
uncinate processus, common bile duct, duodenum/gastric
resection area, mesenteric artery, and portal vein and the
circumferential margin, which is defined as the dorsal resec-
tion margin (peripancreatic fat and fascia of Trietz) or beyond
the anterior pancreatic parenchyma anteriorly (peripancreatic
fat, mesenteric base of the transverse colon, or posterior
peritoneum of the lesser sac). A periampullary tumor was
defined as a tumor of the ampulla of Vater or periampullary
duodenum and distal common bile duct.
Follow-up
Patient follow-up, obtained via office records from the
outpatient clinic, was completed up to May 2002. Patient
demographics, intraoperative factors, pathologic findings,
and postoperative course were evaluated. Parameters such as
blood loss, duration of operation, delayed gastric emptying,
intraoperative and postoperative complications, hospital stay,
hospital mortality, and weight loss were recorded at dis-
charge. Follow-up evaluations were conducted every 3
months following discharge. When signs of recurrent disease
occurred during the interval, a CT scan or MRI was per-
formed.
Statistical Analysis
Data were expressed as median and range. The primary
endpoints in this study were blood loss, operation time, and
hospital stay. The secondary endpoints were delayed gastric
emptying and survival. A power-analysis for these endpoints,
based on data from a former study, had shown that at least 65
patients with pancreatic and periampullary adenocarcinomas
had to be included in each group.15 With this number of
patients, it should be possible to demonstrate (  0.05;  
0.05) that blood loss and operation time will be less (30% and
20%, respectively) with pylorus-preserving pancreaticoduo-
denectomy as compared with the SW resection. This number
of patients was also considered to be sufficient to demonstrate
a reduction of hospital stay. Survival was calculated from the
TABLE 1. Patient Characteristics
Patient Characteristics*
SW
(n  83)
PPPD
(n  87) P Value
Age (y) 62 (27–78) 64 (43–78) 0.269
Gender, male/female 50/37 58/25 0.112
Weight preoperative (kg) 70.6 (46–102) 70.0 (43–110) 0.717
SW, standard Whipple; PPPD, pylorus-preserving pancreatico-
duodenectomy.
*Data given are number of patients or median (range).
TABLE 2. Postoperative Complications, Relaparotomy,
and Mortality
Complications SW (n  83) PDDD (n  87) P Value
Pancreatic fistula 12 (14%) 11 (13%)
GE leakage 2 (1%) 0
Bile leakage 0 2 (2%) 0.528
Postoperative bleeding 6 (7%) 6 (7%) 0.933
Intra-abdominal abscess 8 (10%) 9 (10%) 0.878
Other complications 23 (28%) 19 (22%) 0.375
Relaparotomy 16 (19%) 13 (15%) 0.479
Mortality* 6 (7%) 3 (3%) 0.270
SW, standard Whipple; PPPD, pylorus-preserving pancreaticoduo-
denectomy.
*Operative mortality within 30 d.
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date of surgery using the Kaplan-Meier method and com-
pared with the log-rank test. Percentages were compared
between groups using Fisher exact test or the 2 test. Other
data were compared using the Mann-Whitney U test. The
level of significance was set at P  0.05.
RESULTS
Demographics and preoperative characteristics of this
study are listed in Table 1.
Follow-up Results
Based on the final histologic diagnosis, 29 patients with
benign lesions (14 in the SW group and 15 in the PPPD
group) and 7 with endocrine tumors (3 in the SW group and
4 in the PPPD group) were excluded from the survival
analysis. For long-term follow-up a total of 134 patients with
histologic proven pancreatic and periampullary adenocarci-
noma were included and analyzed. Median follow-up was
18.5 months (range 1–115 months). The median intraopera-
tive blood loss was 2.0 L (0.3–9.5 L) in the SW resection
group and 2.0 L (0.4–21.0 L) in the PPPD group, with a P
value of 0.70. The median operative time was 300 minutes
(range 160–480 minutes.) in the SW group and 300 minutes
(range 130–600 minutes) in the PPPD group (P  0.10).
Number of units of packed red blood cells given during
operation was equal in both groups, with a median of 2 in
each group (P  0.70).
During the postoperative course, there were no differ-
ences in specific procedure-related or general complications.
Sixteen patients in the SW group underwent a relaparotomy
versus 13 patients in the PPPD group (P  0.40; Table 2).
Days of nasogastric intubation were similar in both
groups, with a median of 5 days (range 1–48) in the SW
group and 6 days (range 1–57) in the PPPD group (P  0.80).
There were also no significant differences in days until
regular diet was tolerated.
The incidence of delayed gastric emptying was compa-
rable in both groups, 18 patients in the SW group and 19
patients in the PPPD group (P  0.80). We did find a
significant correlation between DGE and intra-abdominal
complication (postoperative bleeding, abscess and intra-ab-
dominal leakage) (P  0.05).
The median hospital stay was in both groups equal (19
days; P  0.50). Postoperative weight loss was observed in
both groups, with a median of 8 kg in the SW resection group
and 13.5 kg in the PPPD group (P  0.70; Table 3). These
differences equalize during follow-up (Fig. 1).
Pancreatic adenocarcinoma was found in 43 patients in
the SW group and in 47 patients in the PPPD group (Table 4).
Twenty-three patients in the SW group and 21 patients in the
PPPD group were diagnosed with a periampullary carcinoma.
Tumor-positive lymph nodes were found in 38 patients in the
Whipple group versus 37 patients in the PPPD group (P 
TABLE 3. Postoperative Days of Nasogastric Intubation, Days Until Normal Diet, Incidence of
Delayed Gastric Emptying, Postoperative Hospital Stay in Days, and Lapse in Body Weight
Outcome SW PPPD P Value
Days of nasogastric intubation 5 (1–48) 83 6 (1–57) 87 0.835
Days until regular diet tolerated orally 10 (0–54) 83 10 (0–58) 87 0.574
Delayed gastric emptying* 18 (23%) 80 19 (22%) 85 0.800
Hospital stay, days 20 (11–138) 67 18 (4–175) 74 0.488
Body weight on discharge (kg) 67 (44–92) 67 65 (41–98) 74 0.789
Pre-illness body weight (kg) 75 (53–92) 75 79 (50–120) 76 0.571
Preoperative body weight (kg) 71 (46–102) 77 70 (46–102) 81 0.764
*Delayed gastric emptying is defined as nasogastric suction for 10 d or more, or diet on or before the 14th
postoperative day. Data given are median (range) or number of patients. Data given in brackets indicate number of
patients concerned, ie, excluding patients not analyzed
FIGURE 1. Body weight versus time of follow-up.
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0.70). Locoregional tumor-positive lymph nodes were
equally spread in both groups (P  0.60).
Overall operative mortality rate was 5.3%; 6 patients in
the SW group and 3 patients in the PPPD group died within
30 days.
The overall median disease-free survival was 14 months
in the SW-group and 15 months in the PPPD group (P  0.80).
The overall disease-free survival was similar in both groups
(P  0.90). There was no difference in median overall
survival rates between the 2 groups (P  0.90; Fig. 2).
Periampullary cancer was diagnosed in 44 patients, of
whom 21 patients underwent a PPPD and 23 patients a SW
resection. The median disease-free survival was 49 months in
the SW group and 23 months in the PPPD group (P  0.60).
Median survival in the SW group was 17 months versus 29
months in the PPPD group, which is not statistically signif-
icant (P  0.50).
Ninety patients had pancreatic cancer, of whom 47
patients underwent a PPPD and 43 patients a SW. The
median disease-free survival was 7 months in the SW group
FIGURE 2. Overall survival rates for patients with adenocar-
cinoma.
TABLE 4. Pathology
Characteristics SW (n  83) PDDD (n  87) P Value
Malignant
Pancreatic adenocarcinoma 43 (52%) 47 (54%)
Periampullary adenocarcinoma 23 (27%) 21 (24%)
Other malignancy 3 (4%) 4 (5%)
Total 69 (83%) 72 (83%)
Benign
Chronic pancreatitis 10 (12%) 9 (10%)
Benign villous adenoma with dysplasia 4 (5%) 6 (7%)
Total 14 (17%) 15 (17%)
Lymph nodes SW (n  69)* PDDD (n  72)*
Hepatoduodenal ligament 5 (7%) 4 (6%)
Peripancreatic 26 (38%) 25 (35%)
Mesenteric artery/vein 7 (10%) 6 (8%)
Perigastric/pyloric 0 2 (2%)
Tumor-negative lymph nodes 31 (45%) 35 (49%)
SW (n  69) PPPD (n  72)
Margins positive resection
Duodenum/gastric 0 1 (1%)
Pancreatic remnant 1 (1%) 1 (1%)
V.porta/V.mesenterica 2 (3%) 2 (3%)
Mesenteric artery 3 (4%) 4 (6%)
Circumferential 5 (7%) 10 (14%)
Inferior cava vein 1 (1%) 1 (1%)
Total 12/69 (17%) 19/72 (26%) 0.230
SW, standard Whipple; PPPD; pylorus-preserving pancreaticoduodenectomy.
*Data given are number of patients. Peripancreatic: anterior and posterior pancreatoduodenal nodes. Circumferential
margin: posterior resection margin and the margin beyond the pancreatic parenchyma anteriorly.
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and 6 months in the PPPD group (P  0.90) The median
survival was 11 months in the SW group and 12 months in the
PPPD group (P  0.70).
Combining both carcinoma groups, there was no dif-
ference in median overall long-term survival rates between
the 2 randomized groups as shown in Figure 3 (P  0.90).
Tumor positive resection margins were noted in 12
(17%) patients in the SW group and 19 (26%) patients in the
PPPD group (P  0.23). Most of these positive margins were
located at and around the pancreatic resection area, which
was defined as circumferential (Table 4) and not on the
pancreatic remnant (Fig. 4).
DISCUSSION
We hypothesized that PPPD is associated with a reduced
operation time, less blood loss, shorter hospital stay, and a more
physiological food passage. Two smaller randomized studies
reported a shorter operation time and less blood loss, fewer
transfusions, and a lower morbidity for the PPPD. However, the
power of both studies might be considered low.17,18
In this study, the duration of the operation was equal for
the 2 procedures. The median blood loss also did not differ
between the 2 groups (2.0 L; Table 1). Compared with reports
from some large centers,20,26 blood loss in the present series
was 2 times higher; however, in comparison to other multi-
center studies18,27 there are only small differences.
When the results of this study are analyzed, one must
take into consideration the fact that we performed a multi-
center analysis of both large-volume and small-volume cen-
ters, which is a realistic situation in most countries.
The overall operative mortality in this study was 5.3%.
Multicenter studies are often associated with a higher mor-
tality rate, ranging from 5% in Italy27 to 10% in France28 and
17.2% in the United States.29
PPPD has been associated with delayed gastric empty-
ing, an increase in morbidity, and prolonged hospital stay.
Warshaw and Torchiana30 first reported this phenomenon
after their initial study of 8 patients in 1978. According to the
literature, the incidence of delayed gastric emptying is esti-
mated to range between 25% and 70%,12,15,23,30–36 which is
sufficient reason for some to abstain from the PPPD proce-
dure. The incidence of delayed gastric emptying in this study
was equal in the 2 groups, 18 in the Whipple group versus 19
in the PPPD group.
Several factors are thought to play a role in the patho-
physiology of delayed gastric emptying. In the present series,
we found a correlation between delayed gastric emptying and
intra-abdominal complications (P  0.05). This relationship
was reported previously.23,37,38 Gastric dysrhythmias, disrup-
tion of gastroduodenal neural connections, ischemia of the
pylorus muscle, and ligation of the right gastric artery all
have been related to delayed gastric emptying.32,39–42Resec-
tion of the duodenum, the primary production site of most
gastrointestinal hormones, might also play a role in the
pathogenesis of this complication. Yeo et al36 reported in a
randomized trial that administration of erythromycin, a motu-
lin agonist, decreased the incidence of DGE by 37%. Since
this difference was not statistically significant, we did not
include erythromycin as standard therapy.
In the present study, hospital stay, 20 days for the SW
group and 18 days for the PPPD group, was not significantly
different (P  0.50). These results are comparable to other
randomized studies.18,27
An argument in favor of pylorus preservation may be
that patients subsequently have a better nutritional status
FIGURE 3. Periampullary adenocarcinomas (DBD, ampullary
and duodenal carcinomas).
FIGURE 4. Pancreatic adenocarcinomas.
Annals of Surgery • Volume 240, Number 5, November 2004 Pancreaticoduodenectomy Versus Standard Whipple Procedure
© 2004 Lippincott Williams & Wilkins 743
compared with patients after a gastrectomy.23,33 Postopera-
tive weight loss was observed in both groups, with a median
of 8 kg for the Whipple resection group versus 13.5 kg for the
PPPD group. This is not statistically significant (P  0.70).
An argument against the use of PPPD for the resection of
pancreatic tumors is the potential risk of positive duodenal
resection margins,5,14 resulting in lower survival rates. In this
study, 1 patient in the PPPD group had a positive resection
margin at the duodenal site. There were no significant differ-
ences in tumor positive resection margins; subsequently, we
did not detect any significant differences in survival.
According to other randomized studies which com-
pared the PPPD versus SW18 and SW versus the extended
pancreaticoduodenectomy,27 our survival outcomes are
highly comparable. It is important to note that we included
the in-hospital mortality in our survival rate calculation in
contrast to some other studies.21 Furthermore, it should be
noted that adjuvant therapy was not routinely provided in
contrast to other trials.21,43,44 We did not recommend adju-
vant chemotherapy and radiotherapy for our patients since the
outcome of the published trials comparing the effects of
adjuvant chemoradiotherapy to surgery alone24,45 did not
show a statistically significant difference in survival in favor
of the adjuvant therapy.
In conclusion, the incidence of delayed gastric empty-
ing in this study of 170 consecutive patients was similar after
PPPD and Whipple resection. Postoperative nasogastric
drainage period was comparable in both groups. As far as the
duration of operation, blood loss, hospital stay, and postop-
erative weight loss are concerned, there were also no signif-
icant differences. The PPPD appears to be just as radical
compared with the SW procedure. Long-term survival and
disease-free survival did not exhibit significant differences.
Thus, both procedures are equally effective for treatment of
pancreatic cancer.
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